MetaCap

Annexon (ANNX) vs Bicara Therapeutics (BCAX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Annexon (ANNX) has outperformed Bicara Therapeutics (BCAX) over the past year, losing 27.4% versus a loss of 53.2%. Annexon is the larger company by market cap ($591.4 million vs $560.3 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ANNX-27.40%BCAX-53.22%
+75%+6%-62%
Nov 21, 20251 yearNov 20, 2026
ANNX-56.94%BCAX-63.95%
+29%-28%-85%
Sep 9, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ANNX versus BCAX key metrics
MetricANNXBCAX
Share price$3.10$8.44
Market cap$591.37M$560.31M
1-day change-9.09%-7.46%
YTD return-38.25%-49.85%
1-year return-27.40%-53.22%
5-year return-77.37%—
EPS (TTM)$-1.01$-3.46
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-206.69M$-137.95M
52-week high$7.18$30.99
52-week low$3.07$7.87
Distance from 52-week high-56.82%-72.77%
Analyst consensusbuystrong_buy
Avg. price target upside+448.39%+281.16%
Average volume3.36M1.20M
Shares outstanding190.76M66.39M
Employees97103
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ANNX has outperformed BCAX by 25.8 percentage points over the past year.

About Annexon

ANNX stock →

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. The company provides Tanruprubart, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase 2a clinical trial for the treatment of amyotrophic lateral sclerosis.

Health Care · Biotechnology: Pharmaceutical Preparations · 97 employees

About Bicara Therapeutics

BCAX stock →

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 103 employees

ANNX vs BCAX FAQ

Which is bigger, Annexon or Bicara Therapeutics?

Annexon (ANNX) is larger, with a market capitalization of $591.37M compared with $560.31M for Bicara Therapeutics (BCAX).

Which stock has performed better over the past year, ANNX or BCAX?

ANNX returned -27.40% over the past 12 months, compared with -53.22% for BCAX (price return, excluding dividends). Past performance does not predict future results.

Are Annexon and Bicara Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons